19 February 2018 - Chemotherapy could become a thing of the past for up to two in three cancer patients with the government looking at subsidising breakthrough new immunotherapies across multiple cancers.

The medicines called programmed-death ligand 1 therapies — like Keytruda which dramatically extended the life of Liberal Party fundraiser Ron Walker, and Opdivo — use the body’s own immune system to fight cancer.

Currently the $150,000 per patient per year treatments are only subsidised for five types of cancer in the case of Keytruda and eight for Opdivo.

Read Gold Coast Bulletin article